Q32 Bio is a clinical-stage biotechnology enterprise dedicated to discovering and developing biological therapeutics designed to restore healthy immune balance in patients suffering from severe autoimmune and inflammatory diseases. The company targets potent regulators of the adaptive immune system, utilizing its advanced pipeline—such as its lead candidate bempikibart—to treat conditions driven by immune dysfunction, including alopecia areata and atopic dermatitis. Through precision biological engineering, it aims to re-regulate immune pathways and offer transformative treatment alternatives.